易激胶囊对腹泻型肠易激综合征患者白细胞介素-1β、白细胞介素-13的影响

Investigation of Yiji capsule on patients with diarrhea-predominant irritable bowel syndrome and change of interleukin-1β and interleukin-13

目的观察易激胶囊对腹泻型肠易激综合征(IBS)患者白细胞介素-1β(IL-1β)、白细胞介素-13(IL-13)的影响。方法将90例腹泻型IBS患者随机分为2组,对照组45例予枯草杆菌二联活菌肠溶胶囊治疗,治疗组45例在对照组治疗基础上加易激胶囊治疗,2组均治疗4周后观察疗效,比较治疗前后症状评分和血清IL-1β、IL-13水平变化。结果 2组治疗后腹泻、腹痛、腹胀评分均较本组治疗前降低(P<0.05),且治疗组降低明显(P<0.05)。治疗组总有效率86.7%,对照组总有效率64.4%,2组总有效率比较差异有统计学意义(P<0.05),治疗组疗效优于对照组。2组治疗后IL-1β水平较本组治疗前降低(P<0.05),IL-13水平升高(P<0.05);且治疗组治疗后改善更明显(P<0.05)。结论易激胶囊可有效改善腹泻型IBS患者的临床症状,提高临床疗效,降低IL-1β表达水平,增加IL-13表达水平。

Objective To observe Yiji capsule for patients with diarrhea-predominant irritable bowel syndrome and change of interleukin-1β and interleukin-13.Methods 90 Patients with diarrhea-predominant irritable bowel syndrome were randomly divided into two groups.45 cases in the control group were treated by live combined bacillus subtilis and enterococcus faecium enteric-coated capsules treatment（500 mg,three times a day） for 4 weeks.Patients in treatment group（n= 45） were treated by Yiji capsule（3 capsule,three times a day） and live combined bacillus subtilis and enterococcus faecium enteric-coated capsules（500 mg,three times a day） for 4 weeks.The efficacy and the change of symptom score,IL-1β and IL-13 before and after treatment were observed in two groups.Results The symptoms score including diarrhea,abdominal pain and bloating rated after treatment was decreased as compared with that before treatment in two groups（P〈0.05）.The total effective rate in the treatment group（86.7%） was obviously higher than that in the control group（64.4%,P〈0.05）.The level of IL-1βafter treatment were obviously lower than that before treatment in two groups（P〈0.05）.The level of IL-13 after treatment were obviously higher in two groups（P〈0.05）.The improvement of treatment group was more than that of control group after treatment（P〈0.05）.Conclusion Yiji capsule can improve clinical symptoms and the curative effect,regulate the expression of IL-1βand IL-13 in patients diarrhea-predominant irritable bowel syndrome.